Fischer Medical Ventures Limited has announced an internal group reorganisation involving the transfer of shares in its foreign subsidiary to enhance operational efficiency. The company informed stock exchanges on January 21, 2026, about the Executive Business Committee's approval of this strategic move.

Executive Committee Approves Share Transfer

The Executive Business Committee of Fischer Medical Ventures, operating under its delegated authority, has approved the transfer of shares held by the company in PellucidCare Health Innovations Pte Ltd to FlynnCare Health Innovations Private Limited. PellucidCare Health Innovations Pte Ltd, based in Singapore, was formerly known as FMV Healthcare Pte Ltd.

Strategic Rationale and Impact

The company stated that this transfer is being undertaken specifically for administrative and operational efficiency purposes. Fischer Medical Ventures emphasised that the reorganisation represents an internal restructuring between the holding company and its wholly owned subsidiary.

The management highlighted several key aspects of the transaction:

• No change in ultimate ownership of the foreign subsidiary
• No alteration in control or management structure
• No impact on economic interest in the subsidiary
• No material effect on consolidated financials

Regulatory Compliance and Disclosure

Fischer Medical Ventures made this disclosure in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company specifically referenced Schedule III of these regulations in its communication to both BSE Limited and National Stock Exchange of India Limited.

Corporate Structure Implications

The transaction maintains the existing corporate structure hierarchy while optimising internal operations. Since FlynnCare Health Innovations Private Limited is a wholly owned subsidiary of Fischer Medical Ventures Limited, the reorganisation keeps all entities within the same corporate family.

The company secretary and compliance officer, Aravindkumar V, signed the disclosure document digitally on January 21, 2026, ensuring proper documentation and regulatory compliance for this internal restructuring initiative.

Fischer Medical Ventures Limited has announced updates to its board committee composition through a regulatory disclosure dated January 02, 2026. The medical technology company, registered in Visakhapatnam, Andhra Pradesh, provided detailed information about the structure and membership of its key governance committees.

Audit Committee Structure

The Audit Committee has been constituted with seven members, led by Mr. Khairy Jamaluddin Abu Bakar as Chairman. The committee composition reflects a strong independent oversight structure:

Nomination and Remuneration Committee

The Nomination and Remuneration Committee operates with a streamlined five-member structure, maintaining independent oversight for key personnel decisions:

Risk Management Committee Composition

The Risk Management Committee includes both board members and senior management personnel, providing comprehensive risk oversight across operational and strategic areas:

Corporate Governance Framework

The committee structures demonstrate Fischer Medical Ventures' commitment to robust corporate governance practices. The composition ensures appropriate balance between independent oversight and executive participation across all three committees. Mr. Khairy Jamaluddin Abu Bakar serves as Chairman for both the Audit Committee and Nomination and Remuneration Committee, while Ms. Svetlana Rao Raviwada chairs the Risk Management Committee.

The company operates from its registered office in the AP Medtech Zone, Visakhapatnam, with corporate offices located in Chennai, Tamil Nadu. The updated committee compositions reflect the company's ongoing efforts to maintain regulatory compliance and strengthen governance oversight mechanisms.